Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Magrolimab in TP53 mutated AML and MDS

David Sallman • 3 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Pevonedistat

David Sallman, MD, of H. Lee Moffitt Cancer Center, Tampa, FL, outlines the use of magrolimab in TP53 mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in combination with azacitidine. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals